International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
Increased circulating ACE2 and GAS6 are independent predictors of COVID-19 severity.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Martínez-Díaz Irene, Núñez-Delgado Sara, Ortiz-Pérez José T, Morales Albert, Vilardell-Vilà Jordi, Cámara Antonio Cano, Aresté Cristina, Vergara Ander, Llorens-Cebrià Carmen, Hernández-Gonzalez Manuel, Castro Pedro, Sibila Oriol, Fernández Sara, Albacar Nuria, Jacobs-Cachá Conxita, de Frutos Pablo García, Soler María José
Аннотация
OBJECTIVES: Angiotensin-converting enzyme 2 (ACE2) and AXL are the main cell entry receptors for severe acute respiratory syndrome-coronavirus-2. Both receptors can be cleaved by the action of specific metalloproteases. Our study aims to evaluate the association between circulating ACE2 and AXL and its ligand, growth arrest-specific gene 6 (GAS6), with coronavirus disease 2019 (COVID-19) severity at first attendance to the emergency room.
METHODS: We collected serum samples from two large cohorts of patients (study, n = 1652 and external validation, n = 468) who were diagnosed of COVID-19 during 2020-2021. Data from all included patients were used to classify the patients' COVID-19 disease severity, defined as death or admission to the intensive care unit. We measured circulating ACE2 activity by an enzymatic assay and serum levels of sAXL and GAS6 by enzyme-linked immunoassay and we built a multivariate Cox model to predict COVID-19 severity.
RESULTS: Circulating ACE2 activity and GAS6 levels were significantly increased in severe COVID-19. Moreover, both biomarkers were independently associated with COVID-19 severity in a multivariate Cox proportional hazards model. Our model showed high capacity to predict COVID-19 severity (best sensitivity-specificity relation of 82.1-65.8% and area under the curve of 0.81), which was validated in the external cohort (best sensitivity-specificity relation of 90.9-51.7% and area under the curve of 0.76).
CONCLUSION: Increased levels of ACE2 and GAS6 at admission are independently associated with COVID-19 severity, supporting its value as early biomarkers to predict worse disease outcome.
METHODS: We collected serum samples from two large cohorts of patients (study, n = 1652 and external validation, n = 468) who were diagnosed of COVID-19 during 2020-2021. Data from all included patients were used to classify the patients' COVID-19 disease severity, defined as death or admission to the intensive care unit. We measured circulating ACE2 activity by an enzymatic assay and serum levels of sAXL and GAS6 by enzyme-linked immunoassay and we built a multivariate Cox model to predict COVID-19 severity.
RESULTS: Circulating ACE2 activity and GAS6 levels were significantly increased in severe COVID-19. Moreover, both biomarkers were independently associated with COVID-19 severity in a multivariate Cox proportional hazards model. Our model showed high capacity to predict COVID-19 severity (best sensitivity-specificity relation of 82.1-65.8% and area under the curve of 0.81), which was validated in the external cohort (best sensitivity-specificity relation of 90.9-51.7% and area under the curve of 0.76).
CONCLUSION: Increased levels of ACE2 and GAS6 at admission are independently associated with COVID-19 severity, supporting its value as early biomarkers to predict worse disease outcome.